Dose Dependent Changes in Propranolol Half Life when Used As an Adjunct to Neuroleptic Treatment

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1982 Jan 1

PMID 6123130

Authors

D H Staniforth

N J Yorkston

S A Zaki

Affiliations

Soon will be listed here.

References

Vestal R, Kornhauser D, Hollifield J, SHAND D . Inhibition of propranolol metabolism by chlorpromazine. Clin Pharmacol Ther. 1979; 25(1):19-24. DOI: 10.1002/cpt197925119. View

SHAND D, Nuckolls E, OATES J . Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther. 1970; 11(1):112-20. DOI: 10.1002/cpt1970111112. View

Evans G, SHAND D . Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin Pharmacol Ther. 1973; 14(4):487-93. DOI: 10.1002/cpt1973144part1487. View

Atsmon A, Blum I, Steiner M, Latz A, WIJSENBEEK H . Further studies with propranolol in psychotic patients. Relation to initial psychiatric state, urinary catecholamines and 3-methoxy-4-hydroxyphenylglycol excretion. Psychopharmacologia. 1972; 27(3):249-54. DOI: 10.1007/BF00422805. View

Vestal R, Wood A, Branch R, SHAND D, Wilkinson G . Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther. 1979; 26(1):8-15. DOI: 10.1002/cpt19792618. View

Peet M, Middlemiss D, YATES R . Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients. Lancet. 1980; 2(8201):978. DOI: 10.1016/s0140-6736(80)92135-2. View

SHAND D, OATES J . Metabolism of propranolol by rat liver microsomes and its inhibition by phenothiazine and tricyclic antidepressant drugs. Biochem Pharmacol. 1971; 20(7):1720-3. DOI: 10.1016/0006-2952(71)90307-8. View

Yorkston N, Zaki S, Themen J, Havard C . Safeguards in the treatment of schizophrenia with propranolol. Postgrad Med J. 1976; 52 Suppl 4:175-80. View

Yorkston N, Zaki S, Malik M, MORRISON R, Havard C . Propranolol in the control of schizophrenic symptoms. Br Med J. 1974; 4(5945):633-5. PMC: 1612952. DOI: 10.1136/bmj.4.5945.633. View

10.

Atsmon A, Blum I, WIJSENBEEK H, Maoz B, Steiner M, Ziegelman G . The short-term effects of adrenergic-blocking agents in a small group of psychotic patients. Preliminary clinical observations. Psychiatr Neurol Neurochir. 1970; 74(3):251-8. View

11.

Walle T, Conradi E, Walle U, Fagan T, Gaffney T . The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther. 1978; 24(6):668-77. DOI: 10.1002/cpt1978246668. View

12.

Lindstrom L, Persson E . Propranolol in chronic schizophrenia: a controlled study in neuroleptic-treated patients. Br J Psychiatry. 1980; 137:126-30. DOI: 10.1192/bjp.137.2.126. View

13.

Walle T, Conradi E, Walle U, Fagan T, Gaffney T . Propranolol glucuronide cumulation during long-term propranolol therapy: a proposed storage mechanism for propranolol. Clin Pharmacol Ther. 1979; 26(6):686-95. DOI: 10.1002/cpt1979266686. View

14.

Yorkston N, Zaki S, Pitcher D, Gruzelier J, Hollander D, SERGEANT H . Propranolol as an adjunct to the treatment of schizophrenia. Lancet. 1977; 2(8038):575-8. DOI: 10.1016/s0140-6736(77)91427-1. View

15.

Gruzelier J, Thornton S, STANIFORTH D, Zaki S, Yorkston N . Active and passive avoidance learning in controls and schizophrenic patients on racemic propranolol and neuroleptics. Br J Psychiatry. 1980; 137:131-7. DOI: 10.1192/bjp.137.2.131. View

16.

Routledge P, SHAND D . Clinical pharmacokinetics of propranolol. Clin Pharmacokinet. 1979; 4(2):73-90. DOI: 10.2165/00003088-197904020-00001. View

17.

Castleden C, Kaye C, Parsons R . The effect of age on plasma levels of propranolol and practolol in man. Br J Clin Pharmacol. 1975; 2(4):303-6. PMC: 1402604. DOI: 10.1111/j.1365-2125.1975.tb02774.x. View